BeyondSpring Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on cancer therapies, including Plinabulin development, financial results and capital structure. Its Form 10-K and Form 8-K disclosures cover audited consolidated financial statements, quarterly and annual operating results, clinical-program updates, and risk and business information tied to oncology development.
Current reports also record material agreements, registered offerings of ordinary shares, SEED Therapeutics financing and ownership disclosures, and shareholder-vote results from annual meetings. These filings describe governance actions, securities issuances, registration-statement use and other material events affecting BeyondSpring’s public-company reporting.
BeyondSpring Inc. reported another loss-making quarter as a clinical-stage biotech with no product revenue. For the six months ended June 30, 2026, consolidated net loss was $12.4 million, and accumulated deficit reached $411.4 million. Continuing operations held $6.5 million of cash and short-term investments and had net current liabilities of $4.3 million, resulting in a total shareholders’ deficit of $36.0 million.
Management disclosed that recurring losses, limited liquidity and negative working capital raise substantial doubt about the ability to continue as a going concern. The company is cutting spending and seeking additional capital; failure to do so could force reductions in R&D or suspension of operations. Discontinued SEED operations generated $1.0 million of collaboration revenue but a $8.3 million loss in the first half. BeyondSpring expects to collect an additional $28.07 million in tranches from the sale of SEED preferred shares while retaining a minority stake and continuing to focus its main Plinabulin oncology program.
BeyondSpring Inc. reported second-quarter 2026 results and highlighted new clinical data for its lead asset, Plinabulin, in metastatic non-small cell lung cancer (NSCLC). Updated Phase 2 ASCO 2026 data showed a 58.0% two-year overall survival (OS) rate in post–immune checkpoint inhibitor patients, with median progression-free survival of 7.0 months and a generally manageable safety profile. Preclinical AACR 2026 data suggested Plinabulin may enhance the efficacy and tolerability of certain antibody-drug conjugates.
The company is preparing DUBLIN-4, a planned 442-patient confirmatory Phase 3 study of Plinabulin plus docetaxel in non-squamous, EGFR wild-type NSCLC after PD-1/PD-L1 therapy. A leadership transition effective July 1, 2026 installed Min Qiu as Chief Executive Officer, with a mandate focused on advancing DUBLIN-4 and financing activities.
From continuing operations, second-quarter 2026 research and development expenses were $1.0 million, and general and administrative expenses were $0.8 million, leading to a net loss of $1.8 million. For the six months ended June 30, 2026, net loss from continuing operations was $4.1 million. Cash, cash equivalents, and short-term investments totaled $6.5 million as of June 30, 2026, while total liabilities were $50.6 million against total assets of $14.6 million, resulting in a shareholders’ deficit.
BeyondSpring Inc. director Majeti Jiangwen received a grant of stock options to buy 100,000 ordinary shares. The options carry an exercise price of $1.75 per share and expire on July 1, 2036.
According to the grant terms, the options vest in four equal 25% installments on the first, second, third and fourth anniversaries of July 1, 2026, as long as the director continues to serve the company. This is a compensation-related award rather than an open-market share purchase or sale.
BeyondSpring Inc. granted its Chief Executive Officer, Qiu Min, stock options as part of compensation. The award covers 100,000 stock options to purchase ordinary shares at an exercise price of $1.75 per share, expiring on July 1, 2036.
The options were granted for no cash cost to the CEO and will vest in four equal 25% installments on the first, second, third, and fourth anniversaries of July 1, 2026, contingent on continued service with the company. Following this grant, the filing shows 100,000 derivative securities held from this award.
BeyondSpring Inc. reported the initial share holdings of its Chief Executive Officer, Qiu Min, in a Form 3 filing. The filing shows direct ownership of 2,498 Ordinary Shares after the reported entry. This is a baseline disclosure of existing ownership rather than a new buy or sell transaction.
BeyondSpring Inc. filed an initial Form 3 for Chief Financial Officer Li Na (NL), serving as the first formal statement of her beneficial ownership status in the company. The data provided shows no reportable transactions, acquisitions, or derivative positions for this reporting person in this filing.
BeyondSpring Inc. filed an amended report to detail the finalized employment terms for its new Chief Executive Officer, Min Qiu. His agreement provides a base annual salary of $100,000 and eligibility for a target annual bonus equal to 30% of base salary under the company’s bonus programs.
Qiu will receive options to purchase 100,000 ordinary shares, vesting in four equal annual installments under the 2017 Omnibus Incentive Plan. If he is terminated without cause or resigns for good reason, he is entitled to nine months of continued base salary and a pro-rated annual bonus, plus accelerated vesting of unvested options upon certain change-in-control scenarios. Compensation for CFO Na Li remains unchanged.
BeyondSpring Inc. announced a leadership transition centered on advancing its DUBLIN-4 confirmatory Phase 3 trial of Plinabulin for non-small cell lung cancer. Founder and CEO Dr. Lan Huang will step down as Chief Executive Officer effective July 1, 2026, remaining as Chair of the Board while dedicating her operational focus to SEED Therapeutics.
Min Qiu will become Chief Executive Officer and Na Li will become Chief Financial Officer on July 1, 2026, bringing capital markets and cross-border pharma experience. Director Dr. Jiangwen (Jen) Majeti will serve as Vice Chair and receive options to purchase 100,000 ordinary shares, vesting over four years under the 2017 Omnibus Incentive Plan. The company highlights DUBLIN-4, its 442-patient confirmatory Phase 3 study, and prior DUBLIN-3 results showing Plinabulin plus docetaxel doubled two- and three-year survival and reduced grade 4 neutropenia from 33% to 5%, as the strategic focus of the new leadership structure.
BeyondSpring Inc. director and CEO Lan Huang reported an indirect transfer of 260,582 Ordinary Shares as a bona fide gift by the Lan Huang 2022 Grantor Retained Annuity Trust, leaving that trust with no shares. Other indirect holdings remain, including 253,465 shares held by the 2026 SUNSHINE GRAT and 223,291 shares held by the 2024 SPIRIT GRAT for the benefit of Dr. Huang’s children.
BeyondSpring Inc. schedules updated ownership disclosure: This Amendment No. 9 to a Schedule 13G/A reports beneficial ownership and voting arrangements for certain affiliated entities and individuals. The filing states 41,119,820 Ordinary Shares outstanding as of March 31, 2026 and shows Lan Huang and Linqing Jia each beneficially owning 5,787,906 shares (14.1%) through a combination of direct holdings, affiliated entities, trusts and proxies. The filing details recent intra-family trust transfers of 260,582 and 253,465 shares and clarifies shared voting/dispositive arrangements among the reporting persons.